PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Akero Therapeutics, Inc. (AKRO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00973Y1082
CUSIP00973Y108
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$1.62B
EPS (TTM)-$3.24
Total Revenue (TTM)$284.00K
Gross Profit (TTM)$207.00K
EBITDA (TTM)-$190.81M
Year Range$11.25 - $56.66
Target Price$45.78
Short %12.40%
Short Ratio12.39

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Akero Therapeutics, Inc.

Popular comparisons: AKRO vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Akero Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%0.00%10.00%20.00%30.00%40.00%50.00%2024FebruaryMarchAprilMayJune
19.42%
15.16%
AKRO (Akero Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Akero Therapeutics, Inc. had a return of 4.03% year-to-date (YTD) and -57.30% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date4.03%13.65%
1 month17.80%3.82%
6 months19.42%15.17%
1 year-57.30%24.08%
5 years (annualized)N/A13.46%
10 years (annualized)N/A10.86%

Monthly Returns

The table below presents the monthly returns of AKRO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-7.45%24.90%-6.41%-21.26%-5.38%4.03%
2023-9.67%-8.06%-15.93%16.94%-0.36%4.73%-7.05%14.35%1.91%-76.43%40.44%39.49%-57.39%
2022-17.16%1.20%-19.97%-26.07%-17.64%9.38%8.36%14.75%189.79%24.11%10.03%17.85%159.10%
202114.03%3.33%-4.57%6.17%-15.00%-5.23%-13.58%10.73%-5.86%-3.85%-1.07%-0.52%-18.02%
202011.24%-11.83%-2.62%-3.77%24.61%-1.97%40.89%-7.15%-5.55%-13.77%8.40%-10.35%16.24%
20194.53%26.37%14.50%-17.90%2.02%-15.17%12.72%21.15%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AKRO is 19, indicating that it is in the bottom 19% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of AKRO is 1919
AKRO (Akero Therapeutics, Inc.)
The Sharpe Ratio Rank of AKRO is 1616Sharpe Ratio Rank
The Sortino Ratio Rank of AKRO is 2626Sortino Ratio Rank
The Omega Ratio Rank of AKRO is 2222Omega Ratio Rank
The Calmar Ratio Rank of AKRO is 99Calmar Ratio Rank
The Martin Ratio Rank of AKRO is 2222Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Akero Therapeutics, Inc. (AKRO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


AKRO
Sharpe ratio
The chart of Sharpe ratio for AKRO, currently valued at -0.63, compared to the broader market-2.00-1.000.001.002.003.00-0.63
Sortino ratio
The chart of Sortino ratio for AKRO, currently valued at -0.35, compared to the broader market-4.00-2.000.002.004.006.00-0.36
Omega ratio
The chart of Omega ratio for AKRO, currently valued at 0.93, compared to the broader market0.501.001.502.000.93
Calmar ratio
The chart of Calmar ratio for AKRO, currently valued at -0.70, compared to the broader market0.002.004.006.00-0.70
Martin ratio
The chart of Martin ratio for AKRO, currently valued at -1.05, compared to the broader market0.0010.0020.0030.00-1.05
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.20, compared to the broader market-2.00-1.000.001.002.003.002.20
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.12, compared to the broader market-4.00-2.000.002.004.006.003.12
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.39, compared to the broader market0.501.001.502.001.39
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.76, compared to the broader market0.002.004.006.001.76
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.26, compared to the broader market0.0010.0020.0030.008.26

Sharpe Ratio

The current Akero Therapeutics, Inc. Sharpe ratio is -0.63. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Akero Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.002024FebruaryMarchAprilMayJune
-0.63
2.20
AKRO (Akero Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Akero Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%2024FebruaryMarchAprilMayJune
-57.30%
0
AKRO (Akero Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Akero Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Akero Therapeutics, Inc. was 79.99%, occurring on Oct 27, 2023. The portfolio has not yet recovered.

The current Akero Therapeutics, Inc. drawdown is 57.30%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-79.99%Jun 14, 202395Oct 27, 2023
-79.96%Jul 10, 2020478Jun 1, 202293Oct 13, 2022571
-57.16%Aug 29, 2019139Mar 18, 202073Jul 1, 2020212
-32.68%Jan 3, 202365Apr 5, 202346Jun 12, 2023111
-17.41%Dec 19, 20221Dec 19, 20223Dec 22, 20224

Volatility

Volatility Chart

The current Akero Therapeutics, Inc. volatility is 18.23%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%2024FebruaryMarchAprilMayJune
18.23%
2.51%
AKRO (Akero Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Akero Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items